Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males With a Comparator Arm
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Setipiprant (Primary)
- Indications Alopecia
- Focus Proof of concept; Therapeutic Use
- Sponsors Allergan
- 16 Oct 2017 Planned End Date changed from 30 Aug 2018 to 5 Jun 2018.
- 16 Oct 2017 Planned primary completion date changed from 30 Jun 2018 to 5 Apr 2018.
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.